PDL BioPharma EPS - Earnings per Share 2010-2020 | PDLI

PDL BioPharma eps - earnings per share from 2010 to 2020. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
PDL BioPharma Annual EPS
2020 $0.00
2019 $-0.59
2018 $-0.47
2017 $0.71
2016 $0.39
2015 $2.03
2014 $1.86
2013 $1.66
2012 $1.45
2011 $1.15
2010 $0.54
2009 $1.07
PDL BioPharma Quarterly EPS
2020-12-31 $0.00
2020-06-30 $-0.43
2020-03-31 $-0.26
2019-12-31 $-0.44
2019-09-30 $-0.16
2019-06-30 $-0.04
2019-03-31 $0.05
2018-12-31 $0.10
2018-09-30 $0.18
2018-06-30 $-0.76
2018-03-31 $0.01
2017-12-31 $0.14
2017-09-30 $0.14
2017-06-30 $0.39
2017-03-31 $0.04
2016-12-31 $-0.06
2016-09-30 $0.08
2016-06-30 $0.03
2016-03-31 $0.34
2015-12-31 $0.64
2015-09-30 $0.42
2015-06-30 $0.47
2015-03-31 $0.50
2014-12-31 $0.29
2014-09-30 $0.61
2014-06-30 $0.52
2014-03-31 $0.44
2013-12-31 $0.32
2013-09-30 $0.36
2013-06-30 $0.62
2013-03-31 $0.36
2012-12-31 $0.32
2012-09-30 $0.32
2012-06-30 $0.52
2012-03-31 $0.29
2011-12-31 $0.24
2011-09-30 $0.28
2011-06-30 $0.38
2011-03-31 $0.25
2010-12-31 $-0.15
2010-09-30 $0.24
2010-06-30 $0.30
2010-03-31 $0.15
2009-12-31 $0.08
2009-09-30 $0.29
2009-06-30 $0.47
2009-03-31 $0.23
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.000B $0.055B
Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.981B 9.98
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
Biohaven Pharmaceutical Holding (BHVN) United States $9.996B 0.00
QIAGEN (QGEN) Netherlands $9.982B 15.76
Ginkgo Bioworks Holdings (DNA) United States $4.276B 0.00
Emergent Biosolutions (EBS) United States $1.424B 6.09
Arcus Biosciences (RCUS) United States $1.353B 34.31
Myovant Sciences (MYOV) United Kingdom $0.930B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.444B 0.00
Gelesis Holdings (GLS) United States $0.355B 0.00
Zymeworks (ZYME) Canada $0.299B 0.00
Ambrx Biopharma (AMAM) United States $0.138B 0.00
Enzo Biochem (ENZ) United States $0.118B 24.20
SQZ Biotechnologies (SQZ) United States $0.090B 0.00